Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12345678>>>
195 Items
Title  Creator  Group name  Publishing year 
Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation Simon et al. EquipeJPP 2025-02
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference Laurent et al. EquipeJPP 2025-12
MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy J. Constanzo et al. EquipeJPP 2025 (in press)
[68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: Thorough study of the automated radiolabeling reaction conditions Rubira et al. EquipeJPP 2024-04
Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate Souche et al. EquipeJPP 2024-11-20
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice Bardiès et al. EquipeJPP 2024-12-03
Symposium on molecular radiotherapy dosimetry: The first of a series? Bardiès et al. EquipeJPP 2024-04
Serotonergic underpinnings of obsessive-compulsive disorder: A systematic review and meta-analysis of neuroimaging findings Pastre et al. EquipeJPP 2024-11-07
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study Kayal et al. EquipeJPP 2024-01-02
Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE Combet-Curt et al. EquipeJPP 2024-08-01
Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning Gong et al. EquipeJPP 2024-10-23
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting Poty et al. EquipeJPP 2024-10-01
New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer Hébert et al. EquipeJPP 2024-07
Modification of bone architecture following sleeve gastrectomy: a 5-year follow-up Maïmoun et al. EquipeJPP 2024-12-18
LYMPHOSCORE (Lymphoscintigraphy Scoring Reliability) Reliability of a New Qualitative and Semiquantitative Lymphoscintigraphy Scoring System for Primary Lymphedema Guillemard et al. EquipeJPP 2024-09-01
Implementation of dosimetry for molecular radiotherapy; results from a European survey Peters et al. EquipeJPP 2024-01
Extracellular vesicles role in radio(nuclide)therapy Constanzo and Pouget EquipeJPP 2024-12-16
EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses Pouget et al. EquipeJPP 2024-11-12
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617 Fouillet et al. EquipeJPP 2024
[The morbidity and mortality review meetings in radiotherapy departments: Procedure, implementation and prospects of the "Proust" French national project] Belkacemi et al. EquipeJPP 2023-09
[Stereotactic Body Radiation Therapy for less than 3cm (stage I) and 5cm (stage II) inoperable lung tumors: 10 years experience of Montpellier Cancer Institute] Marguerit et al. EquipeJPP 2023-09
[Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas] Hanslik et al. EquipeJPP 2023-10-07
[French careers in oncology radiotherapy: Crossing views] Legouté et al. EquipeJPP 2023-02
[Bladder tumors in the Hérault department: Results of the Hérault tumor registry registration from1987 to 2019] Bruneaux et al. EquipeJPP 2023-08-28
12345678>>>
195 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés